Navigation Links
Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13
Date:7/30/2013

EVANSTON, Ill., July 30, 2013 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13. The new patent, which covers methods of treating major depressive disorder, expires in 2030. GLYX-13 has demonstrated good safety, robust efficacy and rapid onset of effect within hours of a single dose in a Phase II trial.

"Issuance of this new patent extending protection for GLYX-13 is an important development for Naurex and adds significant value to our depression program," noted CEO Derek Small. "In addition, we are continuing to pursue additional patents for GLYX-13 to further fortify our patent portfolio for this promising new drug."

GLYX-13 is a selective NMDA receptor partial agonist, a new class of central nervous system-active compounds discovered by Naurex scientists. It is currently being assessed in a 400-subject Phase Il repeated dose clinical trial. Results from the initial Phase II trial showed that a single administration of GLYX-13 produced statistically significant reductions in depression scores in subjects who had failed treatment with current antidepressants. The reductions were evident within 24 hours and persisted for an average of seven days. In clinical studies to date, GLYX-13 has been well tolerated and has not produced any of the schizophrenia-like effects associated with other drugs that modulate the NMDA receptor.

GLYX-13 was developed based on the work of company founder, Joseph R. Moskal, PhD, and his colleagues at the Falk Center for Molecular Therapeutics at Northwestern University.

U.S. Patent No. 8,492,340 B2 issued on July 23, 2013, is assigned to Northwestern University and exclusively licensed to Naurex Inc.

About Naurex
Naurex Inc. is a clinical-stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NMDA receptor (NMDAR). Lead product GLYX-13 has shown promising antidepressant activity with excellent safety in a Phase Ila clinical trial in subjects who had failed treatment with existing agents. GLYX-13 is currently in a Phase IIb repeated dose clinical trial as adjunctive therapy for major depressive disorder. Oral and IV formulations of Naurex's 2nd-generation compound, NRX-1074, are currently in Phase I clinical studies.  Naurex's patented novel chemistry classes represent a platform for the discovery and development of new CNS therapies and have generated a robust pipeline that includes 3rd- and 4th-generation NMDAR subtype-selective partial agonists with preclinical proof of concept in a number of CNS disorders. For more information, visit www.naurex.com.Contacts:

MediaNaurex Inc.

BLL Partners, LLCAshish Khanna

Barbara LindheimVice President, Corporate Development

(212) 584-2276(847) 871-0377

blindheim@bllbiopartners.comcorporate@naurex.com
'/>"/>

SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
Breaking Medicine News(10 mins):